REG - Haleon PLC - Second Tranche of Share Buyback Programme

HALEONAnnouncement

Thu 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2859Ta&default-theme=true

RNS Number : 2859T  Haleon PLC  31 July 2025

 

Haleon plc: Second Tranche of Share Buyback Programme

 

31 July 2025: Further to the announcement made on 28 March 2025, Haleon plc
(the "Company", or "Haleon") today announces that it is commencing a second
tranche of the share buyback programme to purchase ordinary shares of £0.01
each in the Company (the "Shares") up to an aggregate consideration of £280
million (the "Second Tranche").

 

Approximately £130 million worth of Shares will be repurchased in the Second
Tranche (representing the remainder of the £500 million allocated to share
buybacks in 2025 announced on 27 February 2025). These Shares will be
cancelled.

 

In addition, approximately £150 million worth of Shares will be repurchased
as part of the Second Tranche for the purposes of satisfying Haleon's
obligations under its existing employee share plans in 2026 and 2027. These
Shares will be held as treasury shares (with no voting or dividend rights).

 

The Second Tranche will commence immediately and end no later than 1 December
2025. The purpose of the Second Tranche is to reduce the Company's share
capital.

 

In connection with the Second Tranche, the Company has entered into an
irrevocable agreement with Citigroup Global Markets Limited ("Citi"), for the
purchase by Citi of the Shares. Under the terms of the agreement, any purchase
of Shares by Citi will be carried out on the London Stock Exchange and/or CBOE
Europe Limited. Citi will make trading decisions in relation to the Second
Tranche independently of Haleon with regard to the timing of the purchase,
including during any closed period.

Notes

The maximum number of Shares that may be purchased as part of the Second
Tranche under the Company's existing authority obtained at its Annual General
Meeting held on 28 May 2025 (the "2025 Authority") is 884,608,266, being the
amount of the 2025 Authority not yet utilised as at the date of this
announcement.

 

Any purchases of Shares under the Second Tranche contemplated by this
announcement will be effected within certain pre-set parameters and will be
subject to the terms of the arrangement with Citi. The Buyback Programme will
operate in accordance with (i) the 2025 Authority; (ii) the assimilated UK
Market Abuse Regulation No. 596/2014 and assimilated Commission Delegated
Regulation (EU) 2016/1052 (in each case as they form part of law of the United
Kingdom by virtue of the European Union (Withdrawal) Act 2018) (as amended)
and (iii) Chapter 9 of the UK Financial Conduct Authority's UK Listing Rules.

 

On 26 June 2025, the Company completed the first tranche of its share buyback
programme. Between 28 March 2025 and 26 June 2025, the Company repurchased
51,036,522 Shares for an aggregate consideration of c. £200m. The Company had
also repurchased 44,155,844 Shares from Pfizer for c. £170m by way of an
off-market share buyback on 21 March 2025.

 

Amanda Mellor

Company Secretary

 

 

Enquiries

 

 Investors                                                                         Media

 Jo Russell                               +44 7787 392441                          Zoë Bird                              +44 7736 746167
 Rakesh Patel                             +44 7552 484646                          Victoria Durman                       +44 7894 505730

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)       Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com (http://www.haleon.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCURURRVNUBOUR